Kappa Opioid Receptors Mediate Yohimbine-induced Increases in Impulsivity in the 5-choice Serial Reaction Time Task
Overview
Psychology
Social Sciences
Authors
Affiliations
Dynorphin (DYN), and its receptor, the kappa opioid receptor (KOR) are involved in drug seeking and relapse but the mechanisms are poorly understood. One hypothesis is that DYN/KOR activation promotes drug seeking through increased impulsivity, because many stimuli that induce DYN release increase impulsivity. Here, we systematically compare the effects of drugs that activate DYN/KOR on performance on the 5-choice serial reaction time task (5-CSRTT), a test of sustained attention and impulsivity. In Experiment 1, we determined the effects of U50,488 (0, 2.5, 5 mg/kg), yohimbine (0, 1.25, 2.5 mg/kg), and nicotine (0, 0.15, 0.3 mg/kg) on 5-CSRTT performance. In Experiment 2, we determined the effects of alcohol (0, 0.5, 1.0, 1.5 g/kg) on 5-CSRTT performance before and after voluntary, intermittent alcohol exposure. In Experiment 3, we determined the potential role of KOR in the pro-impulsive effects of yohimbine (1.25 mg/kg) and nicotine (0.3 mg/kg) by the prior administration of the KOR antagonist nor-BNI (10 mg/kg). Premature responding, the primary measure of impulsivity, was reduced by U50,488 and alcohol, but these drugs had a general suppressive effect. Yohimbine and nicotine increased premature responding. Yohimbine-, but not nicotine-induced increases in premature responding were blocked by nor-BNI, suggesting that impulsivity induced by yohimbine is KOR dependent. This may suggests a potential role for KOR-mediated increases in impulsivity in yohimbine-induced reinstatement.
Smith B, Hassler A, Lloyd K, Reyes T Neurotoxicology. 2023; 99:292-304.
PMID: 37981055 PMC: 10842910. DOI: 10.1016/j.neuro.2023.11.008.
Optogenetic and pharmacological interventions link hypocretin neurons to impulsivity in mice.
Tyree S, Jennings K, Gonzalez O, Li S, Nicholson J, von Heimendahl M Commun Biol. 2023; 6(1):74.
PMID: 36658362 PMC: 9852239. DOI: 10.1038/s42003-023-04409-w.
Smith B, Guzman T, Brendle A, Laaker C, Ford A, Hiltz A eNeuro. 2022; 9(5).
PMID: 36216505 PMC: 9581576. DOI: 10.1523/ENEURO.0238-22.2022.
Noradrenergic contributions to cue-driven risk-taking and impulsivity.
Chernoff C, Hynes T, Winstanley C Psychopharmacology (Berl). 2021; 238(7):1765-1779.
PMID: 33649970 DOI: 10.1007/s00213-021-05806-x.
Liu J, Johnson B, Wu R, Seaman Jr R, Vu J, Zhu Q Br J Pharmacol. 2020; 177(15):3403-3414.
PMID: 32246467 PMC: 7348092. DOI: 10.1111/bph.15061.